FTSE MIB
34.276,22 +170,21 (+0,50%) Dow Jones
39.308,00 -23,90 (-0,06%) Nasdaq
18.188,30 +159,54 (+0,88%) Nikkei 225
40.912,37 -1,28 (-0,00%) Petrolio
84,09 +0,21 (+0,25%) Bitcoin EUR
49.958,75 -3.256,87 (-6,12%)
SLNO Dec 2024 50.000 call
- GlobeNewswire
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
In a press release issued earlier this afternoon, the time zone of the FPWR Research Symposium presentation was labeled as Central Time. The correct time zone is Mountain Time. The corrected press release is posted below. REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced an oral presentation at the Fou
- GlobeNewswire
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced an oral presentation at the Foundation for Prader-Willi Research (FPWR) 2023 Research Symposium, being held October 5-6, 2023, in Denver, Colorado. The presentation features results from the recently completed randomized withdrawal period of Study C602,
- GlobeNewswire
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
REDWOOD CITY, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing of the underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross
